Ventis Pharma, INC.
A pharmaceutical and medical-technology company focused on developing and commercializing pain management and procedural-care solutions. The company develops extended-duration, low-toxicity local anesthetic formulations and compounded procedural medications produced under FDA 503B standards, and also designs medical technologies intended to improve operating room workflow and patient securement. Commercial efforts emphasize institutional rollout to hospitals and surgery centers, clinical education, and partnerships with FDA-registered 503B manufacturers.
Industries
Nr. of Employees
small (1-50)
Ventis Pharma, INC.
Newport Beach, California, United States
Products
Enduracaine (extended-duration local anesthetic formulation)
A multi-component local anesthetic formulation combining dilute short-duration and long-duration anesthetic components with epinephrine, developed to provide extended local analgesia with a favorable safety profile.
Sufentanil/ketamine intranasal spray (compounded procedural nasal spray)
A compounded intranasal preparation of sufentanil and ketamine intended for supervised procedural use and produced under FDA 503B outsourcing facility standards to allow needle-free analgesia in institutional settings.
Reusable surgical patient positioning and securement system
A reusable system designed to attach to standard operating table side rails using an articulating mechanism and locking lever to position and secure patient extremities while allowing rapid intraoperative access.
Enduracaine (extended-duration local anesthetic formulation)
A multi-component local anesthetic formulation combining dilute short-duration and long-duration anesthetic components with epinephrine, developed to provide extended local analgesia with a favorable safety profile.
Sufentanil/ketamine intranasal spray (compounded procedural nasal spray)
A compounded intranasal preparation of sufentanil and ketamine intended for supervised procedural use and produced under FDA 503B outsourcing facility standards to allow needle-free analgesia in institutional settings.
Reusable surgical patient positioning and securement system
A reusable system designed to attach to standard operating table side rails using an articulating mechanism and locking lever to position and secure patient extremities while allowing rapid intraoperative access.
Services
Provision of sterile, preservative-free compounded medications produced under FDA 503B standards for institutional use in hospitals, surgery centers, and dental settings.
Services to support institutional adoption including hospital demonstrations, clinical education programs, formulary discussions, and key opinion leader engagement.
Clinical evaluation and demonstrations of operating-room devices to assess positioning time, staff workflow impact, and disposable supply reduction.
Provision of sterile, preservative-free compounded medications produced under FDA 503B standards for institutional use in hospitals, surgery centers, and dental settings.
Services to support institutional adoption including hospital demonstrations, clinical education programs, formulary discussions, and key opinion leader engagement.
Clinical evaluation and demonstrations of operating-room devices to assess positioning time, staff workflow impact, and disposable supply reduction.
Expertise Areas
- Pain management formulation development
- Compounded sterile manufacturing (503B/cGMP)
- Intranasal procedural analgesia
- Clinical trial management and clinical evaluation
Key Technologies
- Extended-duration multi-component local anesthetic formulations
- Intranasal (needle-free) drug delivery
- cGMP 503B sterile compounding
- Reusable surgical patient positioning hardware
News & Updates
Announcement of the U.S. commercial launch of a compounded sufentanil/ketamine intranasal spray manufactured via an FDA-registered 503B outsourcing facility; describes planned institutional rollout and commercialization strategy.
Commercial launch of a reusable operating-room patient positioning system with reported clinical evaluation results on positioning time, securement, and disposable supply reduction.
Recap of company participation at professional conferences where extended-duration local anesthetic formulations were presented and interest from clinicians and potential representatives was reported.
Summary page describing a patent for a kit and method combining dilute solution and powdered long-duration local anesthetic to create an extended-duration anesthetic at the time of administration.
Link and reference to a three-arm randomized clinical trial comparing peripheral nerve blockade and periarticular injection solutions for total knee arthroplasty.
The company reports patents granted or pending in more than 40 countries for its extended-duration local anesthetic formulation.
Announcement of the U.S. commercial launch of a compounded sufentanil/ketamine intranasal spray manufactured via an FDA-registered 503B outsourcing facility; describes planned institutional rollout and commercialization strategy.
Commercial launch of a reusable operating-room patient positioning system with reported clinical evaluation results on positioning time, securement, and disposable supply reduction.
Recap of company participation at professional conferences where extended-duration local anesthetic formulations were presented and interest from clinicians and potential representatives was reported.
Summary page describing a patent for a kit and method combining dilute solution and powdered long-duration local anesthetic to create an extended-duration anesthetic at the time of administration.
Link and reference to a three-arm randomized clinical trial comparing peripheral nerve blockade and periarticular injection solutions for total knee arthroplasty.
The company reports patents granted or pending in more than 40 countries for its extended-duration local anesthetic formulation.